Effect of Fudosteine Combined with Bisoprolol on Blood Gas Indexes and Inflammatory Factors in Patients with Stable Chronic Obstructive Pulmonary Disease

Abstract

Objective: To explore the clinical efficacy of fordostane combined with bisoprolol in the treatment of patients with stable chronic obstructive pulmonary disease (COPD), and their effects on blood gas indexes and inflammatory factors. Methods: 104 patients with stable COPD admitted to our hospital from July 2018 to June 2020 were divided into a control group (n = 52) and an observation group (n = 52) by random number table method. Besides conventional treatment in both groups, control group patients were given bisoprolol and observation group patients received fudosteine combined with Bisoprolol. Clinical efficacy, blood gas indexes, serum indexes and adverse reaction incidence of patients in two groups were compared before and after treatment. Results: The total effective rate in observation group patients was higher than that in control group patients. After treatment, levels of arterial partial pressure of oxygen (PaCO₂), serum amyloid A (SAA), interleukin-6 (IL-6) and malondialdehyde (MDA) in patients in both groups were increased, and the levels in the observation group were higher than those in the control group. Arterial partial pressure of oxygen (PaCO₂), serum amyloid A (SAA), interleukin-6 (IL-6) and malondialdehyde (MDA) levels in both groups of patients were declined after treatment and those in the observation group were lower than those in the control group. The comparison of adverse reaction incidence between patients in two groups was not statistically significant. Conclusion: The clinical efficacy of fordostane with bisoprolol in the treatment of patients with stable COPD is significant, as it improves blood gas index levels and attenuates body inflammatory response.